StreetInsider.com News Articles

Form 8-K PDS Biotechnology Corp For: Aug 21

Tue, 25 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260825/26974735.html

Form 8-K PDS Biotechnology Corp For: Aug 21

Tue, 25 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260825/26974735.html

Form 8-K PDS Biotechnology Corp For: Aug 13

Wed, 19 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260819/26950860.html

Form 8-K PDS Biotechnology Corp For: Aug 13

Wed, 19 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260819/26950860.html

Form 8-K PDS Biotechnology Corp For: Aug 10

Fri, 14 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26924829.html

Form 8-K PDS Biotechnology Corp For: Aug 10

Fri, 14 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26924829.html

PDS Biotechnology Corp (PDSB) PT Lowered to $7 at H.C. Wainwright

Fri, 14 Aug 2026 06:49:33 -0400

H.C. Wainwright analyst Joseph Pantginis lowered the price target on PDS Biotechnology Corp (NASDAQ: PDSB) to $7.00 (from $15.00) while maintaining a Buy rating.

Form 10-Q PDS Biotechnology Corp For: Jun 30

Thu, 13 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26921556.html

Form 10-Q PDS Biotechnology Corp For: Jun 30

Thu, 13 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26921556.html

Form 8-K PDS Biotechnology Corp For: Aug 13

Thu, 13 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26917153.html

Form 8-K PDS Biotechnology Corp For: Aug 13

Thu, 13 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26917153.html

PDS Biotech Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:30:00 -0400

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.

Clinical and Corporate Update

Announced publication of positive clinical and immunological biomarker data from Stage 1 of the NCI-led metastatic colorectal cancer (mCRC) Phase 2, open-label, single-center, non-randomized clinical trial evaluating PDS0301 (formerly PDS01ADC), the Company’s tumor-targeted IL-12 immunocytokine. The clinical trial results, published

PDS Biotech Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 08:30:00 -0400

Clinical and Corporate Update

Announced publication of positive clinical and immunological biomarker data from Stage 1 of the NCI-led metastatic colorectal cancer (mCRC) Phase 2, open-label, single-center, non-randomized clinical trial evaluating PDS0301 (formerly PDS01ADC), the Company’s tumor-targeted IL-12 immunocytokine. The clinical trial results, published

Form 8-K PDS Biotechnology Corp For: Aug 11

Tue, 11 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260811/26902115.html

Form 8-K PDS Biotechnology Corp For: Aug 11

Tue, 11 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260811/26902115.html

PDS Biotech shifts focus to PDS0301 in colorectal cancer

Tue, 11 Aug 2026 08:25:26 -0400

PDS Biotechnology Corporation (Nasdaq: PDSB) announced a strategic refocus, prioritizing its tumor-targeted immunocytokine PDS0301 for metastatic colorectal cancer (mCRC) while seeking external partners for its PDS0101 program.

The Princeton, N.J.-based company said its board and management conducted a comprehensive review of its development portfolio and capital allocation priorities before reaching the decision. As part of the shift, PDS Biotech said it will discontinue its VERSATILE-003 Phase 3 trial for PDS0101 and pursue strategic partnerships or other externally funded arrangements for that program's continued development.

The company cited Phase 2 clinical data generated in collaboration with the National Cancer Institute as a key

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

Tue, 11 Aug 2026 08:25:00 -0400

PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder value

PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D., Chief Executive Officer and Director of PDS Biotech:

“Dear Fellow Shareholders,

Over the past several months, our Board of Directors and management team conducted a comprehensive review of our development portfolio,

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

Tue, 11 Aug 2026 08:25:00 -0400

PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder value

“Dear Fellow Shareholders,

Over the past several months, our Board of Directors and management team conducted a comprehensive review of our development portfolio,

Form 8-K PDS Biotechnology Corp For: Jul 30

Fri, 31 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260731/26850922.html

Form 8-K PDS Biotechnology Corp For: Jul 30

Fri, 31 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260731/26850922.html

Form EFFECT PDS Biotechnology Corp

Wed, 22 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26797633.html

Form EFFECT PDS Biotechnology Corp

Wed, 22 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26797633.html

Form 424B4 PDS Biotechnology Corp

Tue, 21 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260721/26796055.html

Form 424B4 PDS Biotechnology Corp

Tue, 21 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260721/26796055.html

Form S-3 PDS Biotechnology Corp

Fri, 10 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260710/26757676.html